Galderma announced that the FDA has approved Nemluvio (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS)… read more.
UCB, announced that the FDA has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab-bkzx is the first and only approved… read more.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for LEO Pharma’s Anzupgo (delgocitinib) cream for the treatment of adult patients with moderate to severe… read more.
Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether or… read more.
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat adults… read more.
Johnson & Johnson announced that treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate… read more.
Allergan Aesthetics, an AbbVie company announced the FDA approval of Botox Cosmetic for temporary improvement in the appearance of moderate to severe vertical bands connecting the jaw and… read more.
Positive data from the phase III LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolled chronic spontaneous urticaria (CSU) who receive background… read more.
UCB announced that the FDA has approved a 2 mL pre-filled syringe and pre-filled autoinjector, each containing 320 mg of Bimzelx (bimekizumab-bkzx). These new device presentations add to… read more.
UCB, announced the first presentation of two-year data from the Phase III studies, BE HEARD I and BE HEARD II, and their open-label extension, evaluating the efficacy and… read more.
UCB, a global biopharmaceutical company, announced the presentation of new four-year data in patients with moderate to severe plaque psoriasis treated with bimekizumab, an IL-17A and IL-17F inhibitor…. read more.
Eli Lilly and Company announced the FDA approved Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
